Resources

Client Alerts, News Articles, Blog Posts, & Multimedia

Everything you need to know about BMD and the industry.

New Ohio Recovery Housing Rules Take Effect January 1, 2025

Client Alert
January 2, 2025

Ohio is implementing new regulations to enhance accountability and quality in recovery housing. These changes, effective January 1, 2025, will impact certified community behavioral health providers and their referral practices.

The following text is an excerpt from the Ohio Department of Mental Health and Addiction Services, published on December 31, 2024. 

"In accordance with Ohio law (R.C. 5119.394), OhioMHAS has established a registry of recovery housing residences that are accredited (or its equivalent) by certain accreditation organizations or, if newer (in operation for not more than 18 months), are actively engaged in efforts to obtain such accreditation. Beginning Jan. 1, 2025, certified community behavioral health providers are prohibited from referring clients to a recovery housing residence that is not on the statewide recovery housing residence registry at the time of the referral."

Read the full update here.

If your organization needs assistance navigating the new recovery housing rules or ensuring compliance with Ohio’s updated regulations, please contact Member Daphne Kackloudis at dlkackloudis@bmdllc.com.

Ohio Recovery HousingBehavior HealthHealth LawHealthcareDaphne Kackloudis
Client Alert

Name, Image, and Likeness Agreements in Healthcare

November 14, 2025For example, some healthcare providers have begun to utilize "Name, Image, and Likeness" agreements to promote the brand they have created through their healthcare practice.  We have seen the most healthcare NIL activity with longevity and wellness providers, as well as orthopedics.Client Alert

Compounding GLP-1 Drugs - Recent Updates

November 13, 2025Recent guidance from the Ohio Board of Pharmacy (“BOP”) indicates that providers should generally use the FDA approved GLP-1 drug, rather than a non-FDA approved compounded version of the medication. Importantly, if a GLP-1 drug is commercially available, it cannot be copied through compounding. Currently, compounded copies of Tirzepatide and Semaglutide are not permitted.Client Alert

Top Compliance Risks for Ohio Med-Spas in 2025

November 11, 2025The Ohio Board of Pharmacy has increased inspections of med-spas holding Terminal Distributor of Dangerous Drugs (TDDD) licenses, with many facing enforcement actions in 2025. Common issues include purchasing from unlicensed distributors, improper drug storage, inadequate recordkeeping, and insufficient prescriber oversight. Understanding these risks and maintaining compliance can help protect your practice from penalties and license suspension.Client Alert

Pre and Postnuptial Agreements | Necessary, Maybe, What Happened to Forever?

November 7, 2025Both Florida and Ohio now allow clients to enter into a prenuptial or postnuptial agreement prior to marriage or after marriage (Ohio previously did not allow postnuptial agreements). Both documents have statutory guidelines that must be followed in terms of execution and financial disclosure.Client Alert

DHS Ends All Employment Authorization Auto-Extensions

October 29, 2025Effective October 30, 2025, DHS ends all automatic work authorization renewals. The 540-day extension applies only to renewals filed before this date, and there is no grace period for expired EADs filed on or after October 30. Employers must audit EADs, train staff, ensure I-9 compliance, and plan for work authorization gaps. Penalties for noncompliance can be severe.
Older posts